

PROFILE

Santen Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing and marketing of ophthalmic and anti-rheumatic pharmaceuticals to protect and improve people's eyesight and health. We have created innovative pharmaceuticals for all types of ophthalmic disorders and provide information tailored to clinical needs. As a result, we lead Japan's market for prescription ophthalmics, which represent nearly 80 percent of our net sales. With marketing and development bases in Japan, the United States and Europe, backed by first-rate R&D capabilities, we aim to increase our corporate value as a world-class company that delivers unique products worldwide.

Deeply aware of the sanctity of human life, we apply our unique capabilities and technologies in our areas of expertise to contribute to the health and quality of life of patients and their loved ones, and society as a whole.

CONTENTS

FINANCIAL HIGHLIGHTS	1
PRESIDENT'S MESSAGE.....	2
SPECIAL REPORT	5
IMPROVE EARNINGS POWER	
INTERVIEW WITH ICHIRO OTOKOZAWA, MEMBER OF THE BOARD	5
LEVERAGE R&D EXPERTISE	
INTERVIEW WITH TOSHIAKI NISHIHATA, SENIOR CORPORATE OFFICER	9
REVIEW OF OPERATIONS	13
PRESCRIPTION PHARMACEUTICALS	14
OVER-THE-COUNTER PHARMACEUTICALS	22
MEDICAL DEVICES	22
CORPORATE SOCIAL RESPONSIBILITY.....	23
CORPORATE GOVERNANCE	24
BOARD OF DIRECTORS, CORPORATE AUDITORS AND CORPORATE OFFICERS ...	26
FINANCIAL SECTION	27
MAJOR SUBSIDIARIES AND FACILITIES.....	53
CORPORATE INFORMATION	54

A CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements regarding the Company's plans, outlook, strategies and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at the time of publication.

Certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this report. These risks and uncertainties include, but are not limited to, the economic circumstances surrounding the Company's businesses, competitive pressures, changes in related laws and regulations, status of product development programs, and changes in exchange rates.